1 year return (CAGR)
-18.87%
Audax Renovables S.A. Exchange (MC, EUR)
ADX.MC
1.09
-0.01 (-0.91%)
UtilitiesUtilities - Renewable
Loading...
3 year return (CAGR)
-3.42%
5 year return (CAGR)
-5.12%
10 year return (CAGR)
9.27%
Adobe 2026 Q3 – Is sentiment driving the price?
Read MoreMarketcap
486.67M
Price/Sales
0.26
Ent value
1.41B
Price/Book
2.04
Div yield
0.00%
Growth years
-
Div growth
-
FCF payout
-1.24%
Trailing P/E
28.59
PEG
-
Forward P/E
9.50
EPS growth
-6.20%
Stock information
What is a stock exchange? Operation, actors, examples
Read MoreStock chart
Loading...
Stock price data
| Open | 1.10 |
| Daily high | 1.12 |
| Daily low | 1.08 |
| Daily Volume | 367K |
| All-time high | 9.72 |
| 1y analyst estimate | 2.35 |
| Beta | 1.15 |
| EPS (TTM) | 0.03 |
| Dividend per share | 0.00 |
| Ex-div date | 1 Jul 2026 |
| Next earnings date | 28 Feb 2026 |
Downside potential
Loading...
Downside potential data
| ADX.MC | S&P500 | |
| Current price drop from All-time high | -88.77% | -1.06% |
| Highest price drop | -97.22% | -56.47% |
| Date of highest drop | 25 Apr 2013 | 9 Mar 2009 |
| Avg drop from high | -80.32% | -10.67% |
| Avg time to new high | 70 days | 12 days |
| Max time to new high | 4908 days | 1805 days |
News
Global markets are being pulled in several directions at once as central banks rethink policy, trade rules are rewritten and geopolitics keeps volatility on a short fuse. That mix can punish weaker bu...
October 6, 2026
NVS gains global rights to Abogen's ABO2203, expanding its RNA therapeutics push with a potential new approach to B-cell-mediated autoimmune diseases.
October 5, 2026
GE Healthcare Technologies will purchase radiopharmaceutical company Sofie Biosciences to expand into a lucrative therapeutic area.
October 5, 2026
INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES Declaration pursuant to Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des ...
October 5, 2026
NKT now sits against an updated fair value of DKK 952.88 compared with DKK 915.46 previously, which places the internal pricing anchor closer to the DKK 895 to DKK 917 range used in recent Street targ...
October 3, 2026
Tecan Group is back in focus after analysts lifted their fair value estimate from CHF 184.10 to CHF 195.73, reflecting updated price targets across recent research. Several firms have adjusted targets...
October 3, 2026
Healthcare stocks were little changed late Friday afternoon with the NYSE Healthcare Index and the S
October 2, 2026
In exchange for a $575 million payment up front, Abogen Biosciences will furnish Novartis with access to its RNA technology, including an option to license its lead program ABO-2203.
October 2, 2026